

Table Meningococcal vaccine 2019 recommendations by age and risk group

Medically at risk						Healthy individuals					Occupationally at risk	Travellers			
Who should be vaccinated?	Those with medical risk factors for invasive meningococcal disease, including: <ul style="list-style-type: none"> • complement deficiencies • current or future treatment with eculizumab • haemoglobinopathies • haematopoietic stem cell transplant • functional/anatomical asplenia • people living with HIV 					Anyone aged ≥6 weeks who wishes to reduce their risk of invasive meningococcal disease, and in particular the following high-risk demographics: <ul style="list-style-type: none"> • infants aged <2 years • adolescents aged 15–19 years • Aboriginal and Torres Strait Islander children aged <15 years • adults aged 20–24 years who live in close quarters (e.g. military, student accommodation) • adults aged 20–24 years who smoke 					E.g. laboratory workers who handle <i>Neisseria meningitidis</i>	Travellers aged ≥6 weeks travelling to a country endemic for meningococcal A, C, W or Y, as well as Hajj pilgrims			
Which vaccine(s) are recommended?	MenACWY MenB					• MenACWY • MenB					MenACWY MenB	MenACWY			
Which vaccine(s) are NIP funded?	Nil					National Immunisation Program: Nimenrix (MenACWY) is funded at 12 months (GP) and at School Year 10 (14–16 years, school-based program), with catch-up for 15–19 year olds who have not received a dose previously (GP based).					Nil	Nil			
	6 weeks–5 months	6–8 months	9–11 months	12–23 months	≥2 years	6 weeks–5 months	6–8 months	9–11 months	12–23 months	≥2 years					
MenACWY	MenACWY dosing schedule by age at first dose	4 doses Minimum 8-week intervals. 4 th dose at 12 months of age or 8 weeks after 3 rd dose, whichever is later	3 doses Minimum 8-week intervals. 3 rd dose at 12 months of age or 8 weeks after 2 nd dose, whichever is later	3 doses Minimum 8-week intervals. 3 rd dose at 12 months of age or 8 weeks after 2 nd dose, whichever is later	2 doses Minimum 8-week interval	2 doses Minimum 8-week interval	3 doses Minimum 8-week intervals 3 rd dose at 12 months of age or 8 weeks after 2 nd dose, whichever is later	2 doses 2 nd dose at 12 months of age	2 doses 2 nd dose at 12 months of age	Nimenrix: 1 dose Menveo/Menactra: 2 doses, 8 weeks apart	One dose	Dosing depends on presence of medical risk factors or not	Dosing depends on presence of medical risk factors or not		
	Preferred brands (MenACWY)	Menveo or Nimenrix (Menactra not registered for use for this age group)		Menveo, Nimenrix or Menactra*		Menveo or Nimenrix preferred to Menactra*		Menveo or Nimenrix (Menactra not registered for use for this age group)		Menveo, Nimenrix or Menactra*		Menveo or Nimenrix preferred to Menactra*			
	Further MenACWY booster doses required?	Yes, if ongoing increased risk of invasive meningococcal disease If age ≤6 when completed initial MenACWY vaccination course, give MenACWY booster 3 years after primary schedule, then every 5 years If age ≥7 when completed course, give MenACWY booster every 5 years					No, not required					Yes, every 5 years		Yes, every 5 years if ongoing risk	
		6 weeks–5 months	6–11 months	12 months–9 years	≥10 years	6 weeks–11 months	12 months–9 years	≥10 years							
MenB	MenB dosing schedule by age at first dose	Bexsero: 4 doses, minimum 8-week intervals, 4 th dose at 12 months or 8 weeks after 3 rd dose, whichever is later	Bexsero: 3 doses, minimum 8-week intervals, 3 rd dose at 12 months or 8 weeks after 2 nd dose, whichever is later	Bexsero: 2 doses, minimum 8-week interval	Bexsero: 2 doses, minimum 8-week interval Trumenba: 3 doses. Dose 2 should be ≥4 weeks after dose 1. Dose 3 ≥4 months after dose 2 and ≥6 months after dose 1	Bexsero: 3 doses Minimum 8-week intervals, 3 rd dose at 12 months or 8 weeks after 2 nd dose, whichever is later	Bexsero: 2 doses Minimum 8-week interval	Bexsero: 2 doses, minimum 8-week interval Trumenba: 2 doses, minimum 6-month interval		Dosing depends on presence of medical risk factors or not		MenB is not routinely recommended for travellers			

* Menactra should not be co-administered with Prevenar 13

Men meningococcal serogroup

NIP National Immunisation Program

These data are summarised from the online Australian Immunisation Handbook, December 2018.⁴

This table is reprinted from the August 2019 edition of *Australian Prescriber* (vol. 42, no. 4), <https://doi/1018773/austprescr.2019.042>